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A  randomized  trial  was  conducted  to assess  the  immunogenicity  and reactogenicity  of yellow  fever  vac-
cines  (YFV)  given  either  simultaneously  in  separate  injections,  or 30 days  or more  after  a combined
measles–mumps–rubella  (MMR)  vaccine.  Volunteers  were  also  randomized  to YFV  produced  from  17DD
and  WHO-17D-213  substrains.  The  study  group  comprised  1769  healthy  12-month-old  children  brought
to  health  care  centers  in Brasilia  for routine  vaccination.  The  reactogenicity  was of  the  type  and  frequency
expected  for  the  vaccines  and  no  severe  adverse  event  was  associated  to either  vaccine.  Seroconversion
and  seropositivity  30 days  or  more  after  vaccination  against  yellow  fever  was  similar  across  groups
deﬁned  by YFV  substrain.  Subjects  injected  YFV  and  MMR  simultaneously  had  lower seroconversion
rates  –  90%  for rubella,  70%  for yellow  fever  and  61% for mumps  –  compared  with  those  vaccinated  30
days  apart  – 97%  for  rubella,  87%  for  yellow  fever  and  71%  for mumps.  Seroconversion  rates  for  measleseactogenicity
razil
were  higher  than  98%  in both  comparison  groups.  Geometric  mean  titers  for rubella  and  for  yellow  fever
were  approximately  three  times  higher  among  those  who  got  the  vaccines  30 days  apart.  For  measles
and  mumps  antibodies  GMTs  were  similar  across  groups.  MMR’s  interference  in  immune  response  of  YFV
and  YFV’s  interference  in immune  response  of rubella  and  mumps  components  of MMR  had  never  been
reported  before  but are  consistent  with  previous  observations  from  other  live  vaccines.  These  results
datiomay  affect  the  recommen
. IntroductionSimultaneous administration of vaccines in the same visit to
 health service is recommended as a strategy to avoid the loss
f opportunities for vaccination [1]. A minimum of four weeks is
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© 2011 Elsevier Ltd. 
recommended between doses of different live attenuated vaccines
[2]. The Brazilian National Immunization Program (PNI) recom-
mended against intervals shorter than 15 days between the yellow
fever vaccine and other live attenuated vaccines for lack of infor-
mation regarding the interference between these antigens [3]. The
Advisory Committee on Immunization Practices (ACIP, Centers for
Disease Control and Prevention) recommends that injectable or
nasally administered live vaccines be given on the same day or ≥4
weeks apart, to minimize the potential risk for interference [4]. The
World Health Organization (WHO) strongly recommends the yel-
Open access under the Elsevier OA license.low fever vaccine at nine months of age, at the same time of the
measles vaccine in routine immunization in endemic areas [5].
The  high immunogenicity of substrains 17DD yellow fever vac-
cine was conﬁrmed in recent studies in adults and children over
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 years of age [6,7]. A study with children of 9 months showed
o interference when measles and yellow fever vaccines were
dministered simultaneously [8]. In contrast, a multicenter study
n children aged 6–23 months showed a rate of seroconversion
nd geometric mean titers (GMTs) signiﬁcantly lower than those
f adults. The data suggested that simultaneous vaccination against
ellow fever and measles could interfere with the immune response
gainst yellow fever (at that time a monovalent measles vaccine
as administered at 9 months of age) [6]. In Brazil and other coun-
ries the measles vaccine is currently used in combination with the
accine against rubella and mumps. There are no published data on
he interference of the yellow fever vaccine (YFV) and the rubella
nd mumps  vaccines [9].
A  study was conducted to assess the differences in immuno-
enicity and reactogenicity (1) between yellow fever vaccines (YFV)
roduced with WHO  17D-213/77 and 17DD substrains, and (2)
etween YFV (either substrain) injected simultaneously or after 30
ays administering a combined vaccine against measles, rubella
nd mumps  (MMR)  [10]. The postulated effects of MMR  on the
esponse to YFV could not be distinguished for each one of MMR
omponents, but the reciprocal was veriﬁed. For conciseness, this
aper highlighted the results for yellow fever and rubella, as elim-
nation of rubella and congenital rubella syndrome may  require
accination in the age range in which the yellow fever vaccine
s recommended in many countries. Moreover, the interaction of
easles vaccines and YFV had been reported in previous studies.
esults for measles and mumps  are presented brieﬂy.
.  Subjects and methods
This  was a randomized study whose methods were described
reviously [10] and will be presented brieﬂy below. Comparison of
FV produced with WHO  17D-213/77 and 17DD substrains was
ouble-blinded, whereas the comparison between YFV injected
imultaneously or 30 days after MMR  was unblinded.
.1. Study population and eligibility criteria
Fieldwork was conducted from February to July 2006 in nineteen
ublic health centers from Federal District, the only Brazilian State
here routine yellow fever vaccine and MMR  vaccine were given
imultaneously. Children aged 12–23 months who presented for
outine vaccination were invited to participate. The exclusion cri-
eria for the study were based on contraindications for yellow fever
accination [3]: severe malnutrition, immunosuppression, admin-
stration of immunoglobulin or other blood products within 60
ays before or after vaccination, hypersensitivity to gelatin or egg
hicken and derivatives, fever of 37.5 ◦C or more. Children were not
ncluded if obstacles to return for vaccination against yellow fever
r post-vaccination blood collection were anticipated.
.2. Vaccines, randomization and blinding
Regardless of their participation in the study, children received
he MMR  vaccine available for routine immunization in health care
nits. At the time of this ﬁeld study, there were two  MMR  vaccines
vailable: MMRI®, MSD  (measles strain Moraten; mumps  strain
eryl Lynn; rubella strain Wistar 27/3) and vacina combinada con-
ra rubéola, sarampo e caxumbaTM, Bio-Manguinhos/GSK (measles
train Schwarz; mumps  strain RIT 4385; rubella strain Wistar RA
7/3).
Study subjects received a 0.5 mL  dose of yellow fever vaccine
YFV) from one of the two sub-strains, injected subcutaneously in
he deltoid region. YF vaccines were put in identical vials labeled
ith codes generated by a statistician and disclosed only to the
taff who conducted the labeling. The 17DD substrain vaccineine 29 (2011) 6327– 6334
was  produced from the seed lot 993FB013Z (4.70 log10 PFU/0.5-
mL), whereas the 17D substrain vaccine (lot 04UVFAEX34 with
4.91 log10 PFU/0.5-mL) was  produced from the seed batch of the
World Health Organization (WHO 17D-213/77). Children were
given the type of vaccine against yellow fever to which they were
randomly assigned. Study subjects were also randomized to receive
YFV (either substrain) simultaneously or 30 days after MMR  (Fig. 1),
by means of computer generated random numbers, printed and
placed in opaque envelopes, sealed and numbered. After signing the
consent form the envelopes were opened in the order of presenta-
tion of the volunteers. Randomization used permutation blocks of
size 6, ratio of 1:1. The codes were opened after statistical analysis.
Each vial of vaccine was used in only one participant. The MMR  vac-
cine was  administered according to routine immunization services,
without interference from the study.
2.3. Sample size
The  number of participants was  calculated using the following
parameters: beta = 0.2, alpha = 0.05 (two-tailed test), 90% serocon-
version in one group (p1), and minimum difference between the
groups (p1 − p2) of 5 percentage points [11]. The sample size with
a 20% correction for loss of follow up was 1740 children, 870 in each
comparison group.
2.4.  Data collection and outcomes of interest
A questionnaire was  administered before vaccination with
items on age, sex, birth weight and weight at vaccination, immu-
nization history and history of allergies to food and drugs. We  asked
the children’s parents to record daily, in a diary, during the 10 days
after the vaccination, the adverse events expected for the yellow
fever vaccine (fever, vomiting, pain and redness at the injection site
and irritability) and any health problems observed in that period.
The clinical events occurring after this period were recorded on a
postvaccination questionnaire.
Samples  of 4 mL  of blood were collected on the day of MMR
vaccination and 30 days after yellow fever vaccination to titrate
antibodies against yellow fever, rubella, measles and mumps. Thus,
subgroups deﬁned by the interval between the vaccines also dif-
fered in the interval between post-vaccination blood collection and
MMR:  30 days in those who received the vaccines on the same day
and 60 days in those who  received YFV 30 days after.
The titration of antibodies against yellow fever and the anti-
bodies against measles was performed at Virologic Technology
Laboratory of Bio-Manguinhos (LATEV, FIOCRUZ, Rio de Janeiro)
with Plaque Reduction Neutralization Test (PRNT).
PRNT was conducted in serial twofold dilutions starting at 1:5,
in 50 L aliquots of heat inactivated (at 56 ◦C for 30 min) serum,
in 96-well tissue culture plates. A positive monkey serum sample
with yellow fever antibody content calibrated by a WHO  Interna-
tional Reference Preparation, with 1115 mIU/mL was  the standard
serum for each set of tests [12]. For measles the standard serum
contained 3000 mUI/mL [13]. The log10 dilution of the test sera and
the standard serum, which reduced the plaque numbers by 50% rel-
ative to the virus control, was  determined by linear interpolation.
To convert reciprocal dilutions into mIU/mL a unitage constant was
calculated for each assay run, dividing the antibody concentration
in the standard serum by the reciprocal dilution of the standard
serum in that assay run. Results of test sera in reciprocal dilution
were multiplied by the unitage constant to transform into mIU/mL,
which improves comparability of results across assay runs [14,15].
The primary endpoints of the study were antibody titers to
yellow fever in mIU/mL and categories (seropositive: titer higher
than 2.7 log10 mIU/mL or reciprocal dilution higher than 10).
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1943 children recruited, 
received MM R 
1828 children randomized: 
906 assign ed to simult aneous YFV and MMR 
922 assign ed to YFV 30 days  or mo re after MM R 
59 wi thdrew their co nsent  to receive the  YFV  in the study 
22 missed blood collectio n (with drawal, change of  address 
etc.) 
post-vacc ine  se rum test un avail able (insuf fici ent or 
inappro pri ate spe cimens)  for: 
YF: 24;  ru bella:  43; measle s: 54; mumps: 56  
1694  children with  data  on mea sle s, mumps  and  
rubella an tibo dies  
Simult aneous YFV 
and  MMR (N= 839) 
17D-2 13: n= 426 
17DD: n= 413  
YFV 30  days  or mo re 
after MMR (N=852 ) 
17D-213: n= 411 
17DD: n= 441  
1723 childr en wit h data on  yell ow fever 
Simult aneous YFV 
and  MMR (N= 864) 
17D-213:  n= 444  
17DD: n= 42 0 
YFV 30  days  or mor e 
after MM R (N=859 ) 
17D-213: n= 411
17DD: n= 448  
115  excluded bec ause of problems in labeling of 
ser um sample s in one health ca re un it. 
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dig. 1. Flow diagram of a randomized trial of yellow fever vaccines (YFV) injected
his is a description of the assignment of volunteers to allocation groups deﬁned
easles-mumps-rubella vaccine.
eroconversion was deﬁned as quadrupling of pre-vaccination anti-
odies against yellow fever.
Serologic  testing for rubella antibodies (ELISA, Enzygnost®
nti-Rubella-Virus/IgG, Dade Behring, Germany) and for mumps
ntibodies (ELISA, Enzygnost® Anti-Parotitis-Virus/IgG, Dade
ehring, Germany) were performed at the Respiratory Virus Lab-
ratory of Instituto Oswaldo Cruz (FIOCRUZ, Rio de Janeiro), and
he results expressed in International Units per milliliter of serum
IU/mL). The primary endpoints for rubella were post-vaccination
ntibody titers in IU/mL and categories (non-reactive: <4.0 IU/mL;
nconclusive: 4.0–6.5 IU/mL; reactive: >6.5 IU/mL). For mumps, sera
ith antibody titers ≥231 U/mL were considered reactive, implying
hat borderline titers were considered seropositive. Both for rubella
nd for mumps, seroconversion was deﬁned as seropositivity in
ubjects who were non-reactive before vaccination.
.5. Statistical analysis
The  proportion of seroconversion, the geometric mean titer
GMT) and proportion of adverse events after vaccination were
ompared across groups deﬁned by types of yellow fever vac-
ine and interval between vaccinations. The statistical signiﬁcance
f differences in proportions was analyzed by chi-square test,
hereas for the differences in the means of antibody titer
ogarithms the Student’s t test was used. Reverse cumulative dis-
ribution plots were constructed to display the complete range of
erologic data. The level of signiﬁcance was 5%. Data were analyzed
sing SPSS version 13.0 (SPSS, Inc., Chicago, IL).
The complete cohort (“intention-to-treat”) for analysis of
dverse events included children with data on reactogenicity, even
hose who failed to adhere to the study protocol. For the analysis of
mmunogenicity, the cohort consisted of all subjects randomized to
FV types, keeping subjects in the groups to which they were ran-
omly assigned. The interaction of the MMR  vaccine and yellowltaneously or 30 days after a combined measles-mumps-rubella (MMR)  vaccine.
accine type and by time interval between yellow fever vaccine and a combined
fever  was  evaluated by comparing the proportions of seroconver-
sion for yellow fever in individuals in subgroups deﬁned by the
interval between vaccinations. Children without post-vaccination
serological test, or who  violated eligibility criteria were disregarded
in “per-protocol analysis”. With this approach, analysis of immune
response considered the vaccine actually administered, regardless
of randomization group.
The  probability of seroconversion was adjusted for the covari-
ates of interest (age, sex, pre-vaccination seropositivity, time
between pre- and post-vaccination blood collection, and comorbid-
ity) in a logistic regression model. Similarly, the logarithm (base 10)
of post-vaccination antibody titers was modeled by multiple lin-
ear regression for the variable types of vaccines, sex, age, antibody
titers pre-vaccination, time between blood collection, pre- and
post-vaccination and comorbidity. The stepwise entry of variables
in the model and continuation in the ﬁnal model were determined
by their relevance and statistical signiﬁcance (p < 0.20 and p < 0.05,
respectively).
2.6. Ethical considerations
This  study was approved by the Ethics in Research Committees
of the National School of Public Health-Fiocruz (document 236A/03
CEP-FIOCRUZ), and the Ministry of Health of the Federal District
(Document SES-DF CEP-069/2005) authorized by ANVISA and reg-
istered in the International Standard Randomised Controlled Trial
Number Register (ISRCTN 72367932).
3. ResultsFrom a total of 1943 children, 115 in one health center
were disregarded in the analysis because of inconsistencies in
identiﬁcation numbers of blood samples. All the remaining 1828
children received the MMR  (Bio-Manguinhos/GSK, 48.5%, Merck,
6330 J.R.  Nascimento Silva et al. / Vaccine 29 (2011) 6327– 6334
Table 1
Baseline characteristics of study subjects according to type (virus substrain) of yellow fever vaccine (YFV) and to whether YFV was given simultaneously or 30 days after
combined vaccine against measles, rubella and mumps  (MMR).
Characteristic Type of YFV Interval between vaccines
Simultaneous YFV and MMR  YFV 30 days after MMR  Total
Study subjects, n (%) Unvaccinated 23 (1.3) 36 (2.0) 59 (3.2)
17D-213  452 (24.7) 428 (23.4) 880 (48.1)
17DD 432 (23.6) 457 (25.0)  889 (48.6)
Total 906  (49.6) 922 (50.4) 1828 (100.0)
Male,  n (%) Unvaccinated  14 (0.8) 15 (0.8) 29 (1.6)
17D-213  245 (13.3) 246 (13.5) 491 (26.9)
17DD  243 (13.3) 240 (13.1) 483 (26.4)
Total  502 (27.4) 501 (27.5) 1003 (54.9)
Age  in months, mean (SD) Unvaccinated 12.3 (0.9) 12.1 (0.9) 12.2 (0.9)
17D-213 12.2  (0.9) 12.2 (0.8) 12.2 (0.9)
17DD  12.2 (1.1) 12.2 (0.9) 12.2 (1.0)
Total 12.2  (1.0) 12.2 (0.9) 12.2 (0.9)
Birth  weight (g), mean (SD) Unvaccinated 3189 (548) 3269 (546) 3238 (543)
17D-213  3193 (471) 3176 (499) 3185 (484)
17DD  3193 (499) 3177 (492) 3185 (495)
Total  3193 (486) 3180 (497) 3186 (491)
Weight  at vaccination (g), mean
(SD)
Unvaccinated 9926 (1135) 9496 (1307) 9651 (1252)
17D-213 9540 (1203) 9715 (1234)  9627 (1221)
17DD  9632 (1217) 9580 (1247) 9605 (1232)
Total 9593  (1209) 9640 (1244) 9617 (1226)
Seropositive  for yellow fever,
before YFV, n (%)
Unvaccinated 0 (0.0) 5 (0.3) 5 (0.3)
17D-213  45 (2.5) 36 (2.0) 81 (4.5)
17DD  42 (2.3) 55 (3.0) 97 (5.3)
Total  87 (4.8) 96 (5.3) 183 (10.1)
Seropositive  for rubella, before
MMR, n (%)
Unvaccinated –  1 (0.1) 1 (0.1)
17D-213  10 (0.5) 12 (0.7) 22 (1.2)
17DD 9  (0.5) 6 (0.3) 15 (0.8)
Total  19 (1.0) 19 (1.1) 38 (2.1)
Seropositive  for measles, before
MMR, n (%)
Unvaccinated  – – –
17D-213 5 (0.3) – 5 (0.3)
17DD  2 (0.1) 3 (0.2) 5 (0.3)
Total 7  (0.4) 3 (0.2) 10 (0.6)
Seropositive  for mumps, before
MMR, n (%)
Unvaccinated  – – –
17D-213  2 (0.1) 1 (0.0) 3 (0.1)
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Total  5 
5.6%, not recorded, 15.9%) and 59 (3.2%) did not receive yellow
ever vaccine in the study. In the intention-to-treat analysis, we
ncluded the 1769 children who received yellow fever vaccine, and
ere thus randomly assigned to one type of YFV. Among those,
2 (1.2%) did not return for blood sampling after vaccination. Of
hose who returned, 43 (2.5%), 54 (3.1%), 56 (3.2%) and 24 (1.4%) did
ot have post-vaccination serological status for rubella, measles,
umps  and yellow fever, respectively (Fig. 1). The total loss was
3.5% and included subjects who did not return for vaccination or
lood collection, or whose specimens were lost or were insufﬁcient
o perform the serological tests. These losses were not selec-
ive regarding study groups. Six children assigned to vaccination
ith an interval of 30 days received the vaccines simultaneously,
hereas in 5 children the opposite occurred. The 59 volunteers
ost between the two randomization procedures were similar to
hose volunteers randomized to the vaccine against yellow fever,
ccording to gender, age weight, and the proportion seropositive
or rubella and yellow fever (Table 1). The base-line characteristics
ere well-balanced across comparison groups (Table 1). The pro-
ortion of children seropositive to yellow fever before vaccination
as substantially higher than for measles, mumps  and rubella.
.1.  Immune response to the rubella component of MMR
The  proportion of seroconversion and magnitude of immune
esponse (GMT and distribution of postvaccination antibody titers)
or rubella were substantially higher in the group in which YFV
nd MMR  were given 30 days apart, compared to those vaccinated
imultaneously (p < 0.001, Table 2 and Fig. 2). In contrast, the groups(0.2) 5 (0.3) 8 (0.5)
(0.3) 6 (0.3) 11 (0.6)
deﬁned  by the types of yellow fever vaccines showed no signiﬁcant
differences in immune response (p > 0.5, Table 2 and Fig. 2).
In the logistic model for seroconversion only the interval
between vaccines showed a statistically signiﬁcant association
(OR = 3.80, 95% CI: 2.39–6.05). In multivariate linear regression
model the explanatory variables for the logarithm of antibodies
against rubella were interval between administration of YFV and
MMR (p < 0.001), gender (p < 0.001), and logarithm of time between
blood collection and MMR  (p < 0.001).
The  rates of seroconversion for measles were 98.2% in the
group with simultaneous YFV and MMR,  and 99.2% among those
who received YFV 30 days or more after MMR  (p = 0.090). GMTs
were 3.44 IU/mL (95% CI: 3.20–3.70 IU/mL) and 3.19 IU/mL (95% CI:
3.00–3.39 IU/mL), respectively. The seroconversion and GMTs were
similar across groups who  got different substrains of YFV: 98.9%
seroconversion and GMT  of 3.35 IU/mL (95% CI: 3.13–3.58 IU/mL)
in children in the 17D-213 group; 98.4% seroconversion and GMT
equal to 3.28 IU/mL (95% CI: 3.07–3.51 IU/mL) in the 17-DD group
(p = 0.521).
The rates of seroconversion for mumps  were 61.1% in the group
with simultaneous YFV and MMR,  and 70.8% among those who
received YFV 30 days or more after MMR  (p < 0.001). GMTs were
335.5 mIU/mL (95% CI: 314.4–358.0 mIU/mL) and 414.1 mIU/mL
(95% CI: 388.0–442.1 mIU/mL), respectively. The seroconversion
and GMT  were similar across groups who  got different sub-
strains of YFV: 67.0% seroconversion and GMT  of 384.7 mIU/mL
(95% CI: 359.9–411.2 mIU/mL) in children in the 17D-213 group;
65.2% seroconversion and GMT  equal to 362.6 mIU/mL (95% CI:
340.0–386.7 mIU/mL) in the 17-DD group (p = 0.497).
J.R. Nascimento Silva et al. / Vaccine 29 (2011) 6327– 6334 6331
Table 2
Proportion of seroconversion and geometric mean titer (GMT) of antibodies against rubella after combined vaccine against measles, rubella and mumps  (MMR) according
to type (virus substrain) of yellow fever vaccine (YFV) and to whether YFV was  given simultaneously or 30 days after MMR  – complete cohort (n = 1769) and subgroup of
protocol adherers (n = 1686).
Analysis Type of YFV Interval between vaccines
Simultaneous YFV and MMR YFV  30 days after MMR
Seroconversion (%) (95% CI) Complete 17D-213 86.3 (82.8–89.3) 94.9 (92.3–96.8)
Cohort 17DD  86.1 (82.5–89.2) 94.3 (91.7–96.3)
Total  86.2 (83.8–89.0) 94.4 (92.6–95.6)
Protocol  17D-213 90.7 (87.5–93.2) 98.0 (96.2–99.1)
Adherers  17DD 89.8 (86.4–92.5) 96.4 (94.2–97.9)
Total  90.2 (88.0–92.2) 97.2 (95.8–98.2)
GMT  (IU/mL) (95% CI) Complete 17D-213 24.1 (22.0–26.4) 62.2 (57.2–67.5)
Cohort 17DD 25.6  (23.3–28.1) 58.2 (53.2–63.7)
Total  24.8 (23.2–26.5) 60.1 (56.5–63.9)
Protocol  17D-213 24.3 (22.1–26.6) 61.5 (56.6–66.9)
Adherers  17DD 25.5 (23.2–28.0) 58.4 (53.3–63.9)
Total  24.9 (23.3–26.6) 59.9 (56.3–63.7)
Fig. 2. Reverse cumulative distribution of the logarithm (base 10) of rubella and yellow fever antibody titers after vaccination, according to type (virus substrain) of yellow
fever vaccine (YFV) and time interval between the administration YFV and combined vaccine against measles-mumps-rubella (MMR) (complete cohort). These ﬁgures provide
a  complete representation of the performance of the vaccines across comparison groups in the whole range of values of antibody titers.
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Reverse cumulative distribution curves for antibody titers after
MR,  support the ﬁnding of similar immunogenicity across groups
eﬁned by YFV substrains, and groups in which YFV and MMR  were
iven either simultaneously or 30 days apart (data not shown). For
umps, the curves were also consistent with the small difference
n the GMT  shown above.
For each of the three components, the proportions of serocon-
ersion, did not differ substantially in children who received MMR
accine from different producers, whereas GMTs were slightly
igher among those who received the MSD  vaccine (data not
hown).
.2. Immune response to yellow fever vaccine
The proportion of seroconversion and magnitude of immune
esponse (GMT and distribution of postvaccination antibody titers)
ere greater in the group vaccinated with an interval of 30
ays compared to simultaneous vaccination (p < 0.001, Table 3
nd Fig. 2). In contrast, the groups deﬁned by the types of yel-
ow fever vaccines showed no signiﬁcant difference in immune
esponse (p > 0.5, Table 2 and Fig. 2). The logistic model (data not
hown) showed a strong association of seroconversion (OR = 4.53,
5% CI: 3.12–6.57) and post-vaccination seropositivity (OR = 7.60,
5% CI: 5.06–11.40) with the interval between administration of
FV and MMR,  adjusted for the interval between blood collection
nd vaccination with MMR.  In multivariate linear model (data not
hown) log10 post-vaccination antibody titers against yellow fever
ere strongly correlated to the interval between YFV and MMR
p < 0.001), adjusted for the time interval between blood collection
nd MMR  vaccine (p < 0.001). The interaction term for the type of
accine and the interval between YFV and MMR  was  not statistically
igniﬁcant.
.3. Adverse events
Adverse  events were reported in 23% of the children and had
ow or moderate severity: fever (14.2%), vomiting (1.9%), irritabil-
ty (3.3%), pain (2.8%) and redness (1.5%) at the injection site. The
roportion of adverse events was higher in the group vaccinated
imultaneously, but this difference was statistically signiﬁcant only
or fever (16.6% for simultaneous vaccination, 11.8% for vaccination
ith 30-day interval, p = 0.01) and for any signs/symptoms (27.3%
or simultaneous vaccination and 18.8% for vaccination with 30-
ay interval, p = 0.02). The differences in reactogenicity according
o YFV types were small and not statistically signiﬁcant (p > 0.05).
Local events (pain and redness on the injection site) occurred
arlier (1–2 days) than the systemic events (fever, vomiting and
rritability) (4–6 days). Adverse events in the group vaccinated
imultaneously with MMR  and YFV did not differ in average time
f onset of signs/symptoms (p > 0.09). The duration of signs and
ymptoms was on average 2–3 days, with median of 1–2 days. The
ifference between groups deﬁned by interval between vaccines
as small and not statistically signiﬁcant (p > 0.10).
. Discussion
The expanding arsenal of vaccines given in the ﬁrst two  years
f life has been accompanied by extensive research on the possi-
ilities and limitations of combined and simultaneous application
f live attenuated vaccines [16]. This study demonstrated that con-
omitant administration (in separate syringes) of a yellow fever
accine and a combined vaccine against measles, rubella and
umps  induced lower seroconversion rates and GMT  compared
o the immune response to the same vaccines given 30 days apart.
he reduction in the magnitude of immune response was indepen-ine 29 (2011) 6327– 6334
dent  of the substrain of the vaccine against yellow fever and time
of blood collection for serology after vaccination.
The rate of seroconversion to rubella in the group vaccinated
30 days or more apart was  consistent with that observed in other
studies with MMR  vaccines [17–19] but the lower magnitude of the
response to the rubella and mumps  components of MMR  in children
vaccinated simultaneously against yellow fever is unprecedented
in the literature. Signiﬁcant reduction in the response to yellow
fever vaccine in children had been observed after administra-
tion of combined vaccine against smallpox and measles [20], and
simultaneous vaccination against cholera [21,22] and hepatitis B
[23]. Other studies have not found evidence of interference of
YFV simultaneous to or combined with vaccines against smallpox
and diphtheria–tetanus–pertussis [24], measles [8,24–28], hep-
atitis A [29,30], hepatitis B [23,31,32], typhoid fever [33] and
poliomyelitis [32]. Although immunologically plausible, the appar-
ent interference in the adaptive immunity to other vaccines is not
well understood and may  involve the very complex innate immu-
nity mechanisms that can limit the initial contact with a virus and,
therefore, affect the magnitude of the adaptive immune response
[34–37]. A major public health implication of this interference is the
accumulation of a cohort of susceptible subjects long before the age
recommended for revaccination. That could possibly affect disease
control, particularly of yellow fever, for which revaccination every
10 years is recommended, disregarding the age at primovaccination
and the weaker immune response in infants [6,20,25].
Similar to the results of this study, a multicenter study with
the 17DD substrain vaccine showed 88% seroconversion in children
aged 12–23 months and 72% in infants aged 9–11 months [6]. At
the time that study was  conducted the monovalent measles vaccine
was administered at 9 months of age.
As the study outcomes relied on serological tests the implica-
tions of their accuracy results should be considered brieﬂy. PRNT is
the “gold standard” for detection of measles [38] and of yellow fever
antibodies [39], but for yellow fever it lacks the level of standard-
ization of measles PRNT [15] and commercial tests such as those
used for rubella and mumps antibodies. The proportion of reduc-
tion in number of plaques with neutralization, for instance, might
affect the sensitivity of the PRNT and partly explain the variability
of GMT  across studies. Nevertheless, seroconversion may  be a more
robust measure of response to immunization. The pre-vaccination
seropositivity for yellow fever could indicate false positive results
of the PRNT, previous vaccination held outside the Federal District
where the vaccine is given at 9 months of age, and to maternal
antibodies [40]. Randomization safeguarded against selection bias
but misclassiﬁcation of seropositivity might have weakened the
differences between groups. However, with seroconversion as the
outcome we focused on the variation in the immune status after
vaccination and made allowance for pre-vaccination seropositivity.
Systemic adverse events following simultaneous administration
of the vaccines had a similar pattern observed after the vaccine
against yellow fever was given separately. The time of onset of
symptoms, as well as its duration is compatible with events related
to vaccination, but there is no way to distinguish them from signs
and symptoms of coincidental clinical conditions. The frequency
of adverse events following immunization was consistent with
that reported in the literature for yellow fever [41], except for
fever, which was about twice as high. The higher frequency of
signs/symptoms was  a plausible outcome of simultaneous vacci-
nation with four viral agents.
Neutralizing  antibodies against rubella are generally consid-
ered the protective immune response [42]. As titration of these
antibodies is not routinely available, antibody levels (≥15 IU)
measured by other methods are considered to protect against
rubella infection [43]. The reduction of immunogenicity of rubella
vaccine when given simultaneously to yellow fever vaccine can
J.R. Nascimento Silva et al. / Vaccine 29 (2011) 6327– 6334 6333
Table 3
Proportion of seroconversion and geometric mean titer (GMT) of antibodies against yellow fever after YFV according to type (virus substrain) of yellow fever vaccine (YFV)
and  time interval between YFV and combined vaccine against measles, rubella and mumps  (MMR)  – complete cohort (n = 1769) and subgroup of protocol adherers (n = 1648).
Analysis Type of YFV Interval between vaccines
Simultaneous YFV 30 days after MMR
Seroconversion (%) (95% CI) Complete 17D-213 67.3 (62.7–71.6) 80.8 (76.8–84.5)
Cohort 17DD 65.7 (61.0–70.2) 84.7 (81.0–87.9)
Total  66.5 (63.3–69.6) 82.8 (80.2–85.2)
Protocol 17D-213 69.4 (64.9–73.7) 86.5 (82.8–89.7)
Adherers 17DD 70.0 (65.2–74.4) 88.8 (85.4–91.2)
Total  69.7 (66.4–72.8) 87.7 (85.3–89.8)
GMT  (mIU/mL) (95% CI) Complete 17D-213 1019.4 (909.0–1143.2) 3115.8 (2770.8–3503.7)
Cohort 17DD 1105.9 (974.0–1255.6) 3652.5 (3226.5–4134.6)
Total 1060.2 (1015.1–1154.6) 3381.3 (3236.8–3683.7)
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Adherers 17DD 
Total  
ead to a greater proportion of vaccinees with lower titers and,
onsequently, increased risk of reinfection by wild viruses [44].
he reduction of 7 percentage points in seroconversion to rubella,
hen MMR  and YFV were given simultaneously, is signiﬁcant from
mmunological and public health standpoints. In a cohort of 500
irls vaccinated at age 12 observed for 16 years [45] seropositiv-
ty decreased from 100% to 94% and the GMT  declined from 1:110
o 1:18. In a context of low circulation of wild virus, it is possi-
le that children with lower titers after vaccination may  become
usceptible before revaccination.
The seroconversion rate for mumps  in this study is within the
ange reported before for vaccines of Jeryl Lynn strain [46]. The poor
mmune response to the mumps  component of MMR  of two major
anufacturers, contrasted with optimal performance for measles
nd rubella shown above. A thorough review of the laboratory
ethods, and tests with the vaccine in a controlled setting did not
isclose major problems. Nevertheless, MMR  in routine immuniza-
ion rather than in research settings could be more vulnerable to
old chain breach and operational errors, and possibly explain vac-
ination failures. None of those factors seemed to account for the
ifferences in immunogenicity between randomized groups.
.  Conclusions
Although vaccination against measles, mumps and rubella and
ellow fever in general do not coincide in the basic immunization
alendar, the simultaneous application to avoid loss of opportunity
ay be needed in areas of difﬁcult access and when travel to areas
here yellow fever vaccine is required. The results of this study
ndicate the need to revise the guidelines for simultaneous vac-
ination with the vaccines against yellow fever vaccine and MMR.
ostponing the yellow fever vaccine could be considered taking into
ccount the epidemiological context. Revaccination against those
gents in shorter period than currently proposed could be recom-
ended when the risk of disease and poor access did not allow an
nterval of more than 30 days between vaccinations.
These conclusions apply to primary vaccination in children less
han two years old. As primary vaccination against yellow fever
n older children and adults, and a booster dose at any age induce
tronger immune response, interference from other live virus vac-
ines should be less pronounced and possibly irrelevant.
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